Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of therapeutic solutions for physicians and providers to advance patient care in infectious disease. Durata has completed its DISCOVER 1 and DISCOVER 2 global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.
- May 16 2013, 1:44 PM EDT
Paul A. Friedman, M.D. is Elected to Durata Therapeutics' Board of Directors
- May 9 2013, 7:00 AM EDT
Durata Therapeutics, Inc. Reports First Quarter 2013 Financial Results
- May 7 2013, 7:30 AM EDT
Durata Therapeutics to Present at Bank of America Merrill Lynch 2013 Healthcare Conference